SCOTT WATKINS: Open Payments
NPI 1760950604 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,520 in 85 payments from 13 companies in 2025. Trend: 2023 $3,696 · 2024 $1,811 · 2025 $2,520
Food & beverage: $2,515Education: $5
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 12 | $449 |
| ABBVIE INC. | 12 | $368 |
| Otsuka America Pharmaceutical, Inc. | 10 | $342 |
| Teva Pharmaceuticals USA, Inc. | 8 | $286 |
| Vanda Pharmaceuticals Inc. | 12 | $245 |
| Supernus Pharmaceuticals, Inc. | 8 | $186 |
| Neurocrine BioSciences, Inc. | 3 | $180 |
| Janssen Pharmaceuticals, Inc | 4 | $161 |
| Alkermes, Inc. | 7 | $152 |
| Corium, LLC | 5 | $89 |
Products named: VRAYLAR, COBENFY, FANAPT, Qelbree, INGREZZA, REXULTI, INVEGA SUSTENNA, UZEDY.
Industry payments across ID — which companies pay providers there.
